Through gene expression profiling and chromatin immunoprecipitation analysis [16], the Myc oncogene was demonstrated as a direct target of IRF4, and IRF4 was proposed as a master regulator of malignancy-specific gene expression in multiple myeloma. This evidence concerns the gene MYC and plasma cell myeloma.